Company Description
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers.
In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Walter Klemp |
Contact Details
Address: 5300 Memorial Drive, Suite 950 Houston, Texas 77007 United States | |
| Phone | (713) 300-5160 |
| Website | moleculin.com |
Stock Details
| Ticker Symbol | MBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659617 |
| CUSIP Number | 60855D309 |
| ISIN Number | US60855D3098 |
| Employer ID | 47-4671997 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Walter V. Klemp | Co-Founder, Chairman, President and Chief Executive Officer |
| Jonathan P. Foster CPA | Executive Vice President and Chief Financial Officer |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board |
| Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | 8-K | Current Report |
| Aug 1, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 11, 2025 | 8-K | Current Report |
| Jul 11, 2025 | 424B5 | Filing |
| Jul 9, 2025 | 8-K | Current Report |
| Jul 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 8, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 27, 2025 | PRE 14A | Other preliminary proxy statements |